My 2 Favorite Dividend Stocks to Buy in August

The article argues for dividend income despite low market yields, highlighting Pfizer with a ~6% dividend yield backed by nearly $11B in trailing free cash flow, even as the stock has fallen 38% over five years amid the COVID revenue collapse, patent cliff pressures, and >$53B net debt. For Nintendo, it cites a payout policy tied to earnings (greater of 40% of operating earnings or 60% of net profit) and forecasts dividend growth as Nintendo Switch 2 scales, with close to 24M units sold and net income surpassing $3B over the last 12 months. Net-net, it frames both as 5-year+ dividend compounders, but the claims are more valuation/income-focused than a discrete near-term earnings catalyst.

Analysis

PFE reads less like a clean dividend compounder and more like a levered cash-yield story with limited multiple expansion until the balance sheet and earnings base both heal. In this setup, the stock can trade well in a risk-off tape or when rates fall, but the upside is capped because income buyers are underwriting stability, not growth; if refinancing costs, litigation, or another pipeline miss pressure free cash flow, the dividend itself stops being a valuation support and becomes a liability.

NTDOY is the better quality of the two because the payout is tied to an earnings flywheel rather than a fixed yield target. The market usually underestimates how long software monetization can outrun hardware cycles once a platform reaches scale; if attachment remains high, margin expansion can persist for 6-18 months even after the initial console excitement fades. The main risk is that the market is already discounting a smooth monetization curve, so any miss in first-party content cadence or FX translation could compress the re-rate quickly.

The contrarian takeaway is that this is not really a "dividend stock" basket; it is a quality-versus-yield dispersion trade. PFE is the classic value-trap candidate in pharma, while NTDOY is a cash-flow compounder that deserves to be priced more like a platform business than an income stock. If capital is moving into defensives, I would expect better relative performance from higher-quality healthcare balance sheets such as ABBV or MRK than from PFE, and I would watch for dividend-seeker flows to fade once investors focus on earnings durability rather than headline yield.

Key Decisions for Investors

• Initiate a modest 3-6 month long NTDOY / short PFE pair trade. Use it as a relative-quality expression: NTDOY benefits from earnings-linked payout growth, while PFE remains constrained by debt and patent erosion. Add only on a 5-7% NTDOY pullback; cut if PFE shows two consecutive quarters of credible FCF stabilization and debt paydown.
• Do not chase PFE purely for yield. For pharma income exposure, prefer ABBV or MRK over the next 6-12 months unless PFE trades to a materially higher yield with improving leverage metrics. PFE becomes interesting only if net debt/EBITDA trends down for at least two quarters and guidance stops implying flat-to-down core earnings.
• Buy NTDOY on weakness as a structural compounder, not as a high-yield name. Use a 12-18 month horizon and focus on software attach rates and operating margin expansion; if those inflect positively, the dividend story becomes a side effect rather than the thesis.
• Set a watch item on PFE credit sensitivity: if pharma spreads widen or management pauses dividend growth to protect the balance sheet, expect further de-rating. That would confirm the market’s skepticism and favor a short or underweight stance.
• If you want an outright long, prefer NTDOY over PFE and size it against macro risk rather than dividend yield. Falsifier for the long case: weaker-than-expected Switch 2 software monetization or a sustained yen move that masks underlying operating momentum.